CURX Curanex Pharmaceuticals Inc
Fundamentals / CIK 0002025942 / USDCuranex Pharmaceuticals Inc reported $3.10M in total assets and a net loss of $12.33M through December 31, 2025 from SEC EDGAR filings.
Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open CURX in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.
-
Revenue FY 2025-- Dec 31, 2025
-
Operating Income FY 2025-$12.43M Operating profit
-
Net Income FY 2025-$12.33M GAAP bottom line
-
Diluted EPS FY 2025-$8.13 Split-adjusted
-
Free Cash Flow FY 2025-- Operating CF less CapEx
-
Cash & ST Investments Sep 30, 2026$1.58M Total debt: $542K
Annual revenue and net income
2 fiscal years (2024 to 2025), reported in USD.
Financial statements and ratios
Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.
Income Statement (Annual) · Reported in USD · Newest filing period first.
| Income Statement | Dec 31 | Dec 31 |
|---|---|---|
| Research & Development | $2.99M | -- |
| Total Operating Expenses | $4.24M | $365K |
| Operating Income | -$4.24M | -$365K |
| Interest Expense | $8.5K | -- |
| Net Income | -$4.23M | -$362K |
| Basic EPS | -$3.40 | -$0.60 |
| Diluted EPS | -$3.40 | -$0.60 |
| Basic Shares Outstanding | 1.3M | 663.0K |
| Diluted Shares Outstanding | 1.3M | 663.0K |
Income Statement (Quarterly) · Reported in USD · Newest filing period first.
| Income Statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Research & Development | $1.95M | $2.59M | $2.26M | -- | $677K | -- | -- | -- |
| Total Operating Expenses | $2.83M | $3.33M | $3.18M | $3.09M | $951K | $58K | $137K | -- |
| Operating Income | -$2.83M | -$3.33M | -$3.18M | -$3.09M | -$951K | -$58K | -$137K | -- |
| Interest Expense | -- | -- | -- | $0 | $4.1K | $3.1K | $1.4K | -- |
| Net Income | -$2.82M | -$3.29M | -$3.15M | -$3.07M | -$954K | -$60K | -$138K | -$146K |
| Basic EPS | -$1.86 | -$2.40 | -$2.20 | -- | -$0.75 | $0.00 | -$0.20 | -- |
| Diluted EPS | -$1.86 | -$2.40 | -$2.20 | -- | -$0.75 | $0.00 | -$0.20 | -- |
| Basic Shares Outstanding | 1.5M | 1.4M | 1.4M | -- | 1.3M | 1.2M | 1.2M | -- |
| Diluted Shares Outstanding | 1.5M | 1.4M | 1.4M | -- | 1.3M | 1.2M | 1.2M | -- |
Balance Sheet (Annual) · Reported in USD · Newest filing period first.
| Balance Sheet | Dec 31 | Dec 31 |
|---|---|---|
| Cash & Cash Equivalents | $5.00M | $149K |
| Cash & Short-Term Investments | $5.00M | $149K |
| Other Current Assets | -- | $368K |
| Total Current Assets | $11.23M | $518K |
| Total Non-Current Assets | $353K | $0 |
| Total Assets | $11.58M | $518K |
| Accounts Payable | $2.4K | $5.0K |
| Total Current Liabilities | $137K | $15K |
| Total Non-Current Liabilities | $224K | $0 |
| Total Liabilities | $361K | $15K |
| Total Debt (incl. Leases) | $347K | -- |
| Common Stock | $142 | $2.4K |
| Retained Earnings | -$4.85M | -$622K |
| Total Stockholders' Equity | $11.22M | $503K |
| Total Equity | $11.22M | $503K |
Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.
| Balance Sheet | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2024-12-31 |
|---|---|---|---|---|---|---|---|
| Cash & Cash Equivalents | $1.58M | $2.94M | $4.00M | $5.00M | $5.80M | $109K | $149K |
| Cash & Short-Term Investments | $1.58M | $2.94M | $4.00M | $5.00M | $5.80M | $109K | $149K |
| Other Current Assets | -- | -- | -- | -- | -- | $596K | $368K |
| Total Current Assets | $2.56M | $4.79M | $8.09M | $11.23M | $14.42M | $711K | $518K |
| Total Non-Current Assets | $541K | $281K | $318K | $353K | $60K | $76K | $0 |
| Total Assets | $3.10M | $5.07M | $8.41M | $11.58M | $14.48M | $787K | $518K |
| Accounts Payable | -- | $154 | $8.4K | $2.4K | $114K | $269 | $5.0K |
| Total Current Liabilities | $143K | $104K | $129K | $137K | $186K | $76K | $15K |
| Total Non-Current Liabilities | $409K | $182K | $204K | $224K | $0 | $406K | $0 |
| Total Liabilities | $552K | $286K | $333K | $361K | $186K | $482K | $15K |
| Total Debt (incl. Leases) | $542K | $276K | $311K | $347K | $61K | $76K | -- |
| Common Stock | $157 | $2.8K | $2.8K | $142 | $2.8K | $2.4K | $2.4K |
| Retained Earnings | -$14.10M | -$11.29M | -$8.00M | -$4.85M | -$1.77M | -$820K | -$622K |
| Total Stockholders' Equity | $2.55M | $4.79M | $8.08M | $11.22M | $14.29M | $305K | $503K |
| Total Equity | $2.55M | $4.79M | $8.08M | $11.22M | $14.29M | $305K | $503K |
Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.
| Cash Flow Statement | Dec 31 | Dec 31 |
|---|---|---|
| Net Income | -$4.23M | -$362K |
| Change in Payables | -$2.6K | $5.0K |
| Operating Cash Flow | -$10.48M | -$556K |
| Common Stock Issued | -- | $630K |
| Financing Cash Flow | $15.31M | $630K |
| Net Change in Cash | $4.82M | $75K |
Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.
| Cash Flow Statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$2.82M | -$3.29M | -$3.15M | -$3.07M | -$954K | -$60K | -$138K | -$146K |
| Stock-Based Compensation | $154K | $0 | $9.8K | -- | -- | -- | -- | -- |
| Change in Payables | -$154 | -$8.2K | $6.0K | -$112K | $114K | -$126K | $121K | -- |
| Operating Cash Flow | -$1.36M | -$1.08M | -$955K | -$857K | -$9.19M | -$290K | -$150K | -- |
| Financing Cash Flow | -- | -- | -- | $0 | $14.91M | $200K | $200K | -- |
| Net Change in Cash | -$1.36M | -$1.08M | -$955K | -$857K | $5.72M | -$90K | $50K | -- |
Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.
| Ratios & Growth | Dec 31 | Dec 31 |
|---|---|---|
| Return on Equity (ROE) | -37.7% | -71.8% |
| Return on Assets (ROA) | -36.5% | -69.8% |
| Current Ratio | 81.93x | 35.54x |
| Quick Ratio | 36.49x | 10.22x |
| Debt to Equity | 0.03x | -- |
Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.
| Ratios & Growth | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -484.4% | -218.7% | -89.6% | -37.7% | -9.1% | -142.4% | -- | -71.8% |
| Return on Assets (ROA) | -398.1% | -206.3% | -86.0% | -36.5% | -9.0% | -55.3% | -- | -69.8% |
| Current Ratio | 17.84x | 45.95x | 62.87x | 81.93x | 77.53x | 9.37x | -- | 35.54x |
| Quick Ratio | 11.02x | 28.17x | 31.07x | 36.49x | 31.19x | 1.43x | -- | 10.22x |
| Debt to Equity | 0.21x | 0.06x | 0.04x | 0.03x | 0.00x | 0.25x | -- | -- |